Across TCGA pan-cancer cohorts, COL6A5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated COL6A5 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher COL6A5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated COL6A5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, KICH, and STAD are the cancer types where COL6A5 Mutation most reproducibly stratifies survival.